Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.

Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, Manga S, Skrahina A, Diktanas S, Codecasa LR, Aleksa A, Bruchfeld J, Koleva A, Piubello A, Udwadia ZF, Akkerman OW, Belilovski E, Bernal E, Boeree MJ, Loidi JC, Cai Q, Cebrian Gallardo JJ, Dara M, Davidavičienė E, Forsman LD, De Los Rios Jefe J, Denholm J, Drakšienė J, Duarte R, Elamin SE, Salinas NE, Ferrarese M, Filippov A, Garcia A, García-García JM, Gaudiesiute I, Gavazova B, Gayoso R, Rosso RG, Gruslys V, Gualano G, Hoefsloot W, Jonsson J, Khimova E, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Marchese V, Robles EM, Matteelli A, Mazza-Stalder J, Moschos C, Munoz-Torrico M, Hamdan HM, Nakčerienė B, Nicod L, Marcos MN, Palmero DJ, Palmieri F, Papavasileiou A, Payen MC, Pontarelli A, Quirós S, Rendon A, Saderi L, Šmite A, Solovic I, Souleymane MB, Tadolini M, van den Boom M, Vescovo M, Viggiani P, Yedilbayev A, Zablockis R, Zhurkin D, Zignol M, Visca D, Spanevello A, Caminero JA, Alffenaar JW, Tiberi S, Centis R, D'Ambrosio L, Pontali E, Sotgiu G, Migliori GB.

Eur Respir J. 2019 Oct 10. pii: 1901522. doi: 10.1183/13993003.01522-2019. [Epub ahead of print]

PMID:
31601711
2.

Individualised dosing algorithm and personalised treatment of high-dose rifampicin for tuberculosis.

Svensson RJ, Niward K, Davies Forsman L, Bruchfeld J, Paues J, Eliasson E, Schön T, Simonsson USH.

Br J Clin Pharmacol. 2019 Oct;85(10):2341-2350. doi: 10.1111/bcp.14048. Epub 2019 Jul 25.

PMID:
31269277
3.

A new mathematical model to identify contacts with recent and remote latent tuberculosis.

Fröberg G, Wahren Borgström E, Chryssanthou E, Correia-Neves M, Källenius G, Bruchfeld J.

ERJ Open Res. 2019 Jun 10;5(2). pii: 00078-2019. doi: 10.1183/23120541.00078-2019. eCollection 2019 Apr.

4.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.

Akkerman O, Aleksa A, Alffenaar JW, Al-Marzouqi NH, Arias-Guillén M, Belilovski E, Bernal E, Boeree MJ, Borisov SE, Bruchfeld J, Cadiñanos Loidi J, Cai Q, Caminero JA, Cebrian Gallardo JJ, Centis R, Codecasa LR, D'Ambrosio L, Dalcolmo M, Danila E, Dara M, Davidavičienė E, Davies Forsman L, De Los Rios Jefe J, Denholm J, Duarte R, Elamin SE, Ferrarese M, Filippov A, Ganatra S, Garcia A, García-García JM, Gayoso R, Giraldo Montoya AM, Gomez Rosso RG, Gualano G, Hoefsloot W, Ilievska-Poposka B, Jonsson J, Khimova E, Kuksa L, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Manga S, Marchese V, Martínez Robles E, Maryandyshev A, Matteelli A, Migliori GB, Mullerpattan JB, Munoz-Torrico M, Mustafa Hamdan H, Nieto Marcos M, Noordin NM, Palmero DJ, Palmieri F, Payen MC, Piubello A, Pontali E, Pontarelli A, Quirós S, Rendon A, Skrahina A, Šmite A, Solovic I, Sotgiu G, Souleymane MB, Spanevello A, Stošić M, Tadolini M, Tiberi S, Udwadia ZF, van den Boom M, Vescovo M, Viggiani P, Visca D, Zhurkin D, Zignol M; members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring.

Int J Infect Dis. 2019 Jun;83:72-76. doi: 10.1016/j.ijid.2019.03.036. Epub 2019 Apr 3.

5.

Biomarkers for tuberculosis: the case for lipoarabinomannan.

Correia-Neves M, Fröberg G, Korshun L, Viegas S, Vaz P, Ramanlal N, Bruchfeld J, Hamasur B, Brennan P, Källenius G.

ERJ Open Res. 2019 Feb 11;5(1). pii: 00115-2018. doi: 10.1183/23120541.00115-2018. eCollection 2019 Feb. Review.

6.

Diagnostic pathways and delay among tuberculosis patients in Stockholm, Sweden: a retrospective observational study.

Wikell A, Åberg H, Shedrawy J, Röhl I, Jonsson J, Berggren I, Buxbaum C, Lönnroth K, Bruchfeld J.

BMC Public Health. 2019 Feb 4;19(1):151. doi: 10.1186/s12889-019-6462-5.

7.

Guidance for programmatic management of latent tuberculosis infection in the European Union/European Economic Area.

Rosales-Klintz S, Bruchfeld J, Haas W, Heldal E, Houben RMGJ, van Kessel F, Mandelbaum M, Matteelli A, Migliori GB, Oordt-Speets A, Solovic I, Vašáková M, Verver S, de Vlas SJ, Vonk Noordegraaf-Schouten MJM, de Vries G, Zenner D, van der Werf MJ.

Eur Respir J. 2019 Jan 17;53(1). pii: 1802077. doi: 10.1183/13993003.02077-2018. Print 2019 Jan. No abstract available.

PMID:
30655449
8.

Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades.

Forsman LD, Jonsson J, Wagrell C, Werngren J, Mansjö M, Wijkander M, Groenheit R, Hammar U, Giske CG, Schön T, Bruchfeld J.

Clin Infect Dis. 2019 Sep 27;69(8):1394-1402. doi: 10.1093/cid/ciy1068.

PMID:
30561569
9.

Treatment of latent tuberculosis with 12 weeks isoniazid/rifapentine in clinical practice.

Fröberg G, Jansson L, Bruchfeld J.

Eur Respir J. 2019 Feb 7;53(2). pii: 1801128. doi: 10.1183/13993003.01128-2018. Print 2019 Feb. No abstract available.

PMID:
30409821
10.

Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis.

Pradipta IS, Forsman LD, Bruchfeld J, Hak E, Alffenaar JW.

J Infect. 2018 Dec;77(6):469-478. doi: 10.1016/j.jinf.2018.10.004. Epub 2018 Oct 16.

PMID:
30339803
11.

Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study.

Davies Forsman L, Niward K, Hu Y, Zheng R, Zheng X, Ke R, Cai W, Hong C, Li Y, Gao Y, Werngren J, Paues J, Kuhlin J, Simonsson USH, Eliasson E, Alffenaar JW, Mansjö M, Hoffner S, Xu B, Schön T, Bruchfeld J.

BMJ Open. 2018 Oct 4;8(9):e023899. doi: 10.1136/bmjopen-2018-023899.

12.

Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting.

Niward K, Davies Forsman L, Bruchfeld J, Chryssanthou E, Carlström O, Alomari T, Carlsson B, Pohanka A, Mansjö M, Jonsson Nordvall M, Johansson AG, Eliasson E, Werngren J, Paues J, Simonsson USH, Schön T.

J Antimicrob Chemother. 2018 Oct 1;73(10):2838-2845. doi: 10.1093/jac/dky268.

PMID:
30124844
13.

Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery.

Borisov SE, D'Ambrosio L, Centis R, Tiberi S, Dheda K, Alffenaar JW, Amale R, Belilowski E, Bruchfeld J, Canneto B, Denholm J, Duarte R, Esmail A, Filippov A, Davies Forsman L, Gaga M, Ganatra S, Igorevna GA, Lazaro Mastrapa B, Manfrin V, Manga S, Maryandyshev A, Massard G, González Montaner P, Mullerpattan J, Palmero DJ, Pontarelli A, Papavasileiou A, Pontali E, Romero Leyet R, Spanevello A, Udwadia ZF, Viggiani P, Visca D, Sotgiu G, Migliori GB.

J Infect. 2019 Jan;78(1):35-39. doi: 10.1016/j.jinf.2018.08.003. Epub 2018 Aug 7.

PMID:
30096332
14.

Plasma Levels of Rifampin Correlate with the Tuberculosis Drug Activity Assay.

Niward K, Ek Blom L, Davies Forsman L, Bruchfeld J, Eliasson E, Schön T, Chryssanthou E, Paues J.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00218-18. doi: 10.1128/AAC.00218-18. Print 2018 May.

15.

Tuberculosis Risk in Ankylosing Spondylitis, Other Spondyloarthritis, and Psoriatic Arthritis in Sweden: A Population-Based Cohort Study.

de Vries MK, Arkema EV, Jonsson J, Bruchfeld J, Jacobsson LTH, Askling J; ARTIS Study Group.

Arthritis Care Res (Hoboken). 2018 Oct;70(10):1563-1567. doi: 10.1002/acr.23487. Epub 2018 Sep 4.

16.

A borderline range for Quantiferon Gold In-Tube results.

Jonsson J, Westman A, Bruchfeld J, Sturegård E, Gaines H, Schön T.

PLoS One. 2017 Nov 2;12(11):e0187313. doi: 10.1371/journal.pone.0187313. eCollection 2017.

17.

Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.

Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D'Ambrosio L, Centis R, Sotgiu G, Tiberi S, Alffenaar JW, Maryandyshev A, Belilovski E, Ganatra S, Skrahina A, Akkerman O, Aleksa A, Amale R, Artsukevich J, Bruchfeld J, Caminero JA, Carpena Martinez I, Codecasa L, Dalcolmo M, Denholm J, Douglas P, Duarte R, Esmail A, Fadul M, Filippov A, Davies Forsman L, Gaga M, Garcia-Fuertes JA, García-García JM, Gualano G, Jonsson J, Kunst H, Lau JS, Lazaro Mastrapa B, Teran Troya JL, Manga S, Manika K, González Montaner P, Mullerpattan J, Oelofse S, Ortelli M, Palmero DJ, Palmieri F, Papalia A, Papavasileiou A, Payen MC, Pontali E, Robalo Cordeiro C, Saderi L, Sadutshang TD, Sanukevich T, Solodovnikova V, Spanevello A, Topgyal S, Toscanini F, Tramontana AR, Udwadia ZF, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2017 May 21;49(5). pii: 1700387. doi: 10.1183/13993003.00387-2017. Print 2017 May.

18.

Tuberculosis in migrants in low-incidence countries: epidemiology and intervention entry points.

Lönnroth K, Mor Z, Erkens C, Bruchfeld J, Nathavitharana RR, van der Werf MJ, Lange C.

Int J Tuberc Lung Dis. 2017 Jun 1;21(6):624-637. doi: 10.5588/ijtld.16.0845. Review.

PMID:
28482956
19.

Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis.

Davies Forsman L, Bruchfeld J, Alffenaar JC.

Eur Respir J. 2017 Apr 26;49(4). pii: 1700173. doi: 10.1183/13993003.00173-2017. Print 2017 Apr. No abstract available.

20.

Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?

Zuur MA, Akkerman OW, Davies Forsman L, Hu Y, Zheng R, Bruchfeld J, Tiberi S, Migliori GB, Alffenaar JC.

Eur Respir J. 2016 Oct;48(4):1230-1233. doi: 10.1183/13993003.00833-2016. Epub 2016 Sep 1. No abstract available.

21.

Emetine Di-HCl Attenuates Type 1 Diabetes Mellitus in Mice.

Hudson LK, Dancho ME, Li J, Bruchfeld JB, Ragab AA, He MM, Bragg M, Lenaghan D, Quinn MD, Fritz JR, Tanzi MV, Silverman HA, Hanes WM, Levine YA, Pavlov VA, Olofsson PS, Roth J, Al-Abed Y, Andersson U, Tracey KJ, Chavan SS.

Mol Med. 2016 Oct;22:585-596. doi: 10.2119/molmed.2016.00082. Epub 2016 Jun 10.

22.

Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

Davies Forsman L, Giske CG, Bruchfeld J, Schön T, Juréen P, Ängeby K.

Int J Mycobacteriol. 2015 Mar;4 Suppl 1:80-1. doi: 10.1016/j.ijmyco.2014.10.018. Epub 2014 Nov 11.

23.

Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.

Niward K, Ängeby K, Chryssanthou E, Paues J, Bruchfeld J, Jureen P, Giske CG, Kahlmeter G, Schön T.

J Antimicrob Chemother. 2016 Feb;71(2):333-8. doi: 10.1093/jac/dkv353. Epub 2015 Nov 3.

PMID:
26538509
24.

Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.

Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, Cavalcante S, Cedillos R, Chaisson R, Chee CB, Chesire L, Corbett E, Dara M, Denholm J, de Vries G, Falzon D, Ford N, Gale-Rowe M, Gilpin C, Girardi E, Go UY, Govindasamy D, D Grant A, Grzemska M, Harris R, Horsburgh CR Jr, Ismayilov A, Jaramillo E, Kik S, Kranzer K, Lienhardt C, LoBue P, Lönnroth K, Marks G, Menzies D, Migliori GB, Mosca D, Mukadi YD, Mwinga A, Nelson L, Nishikiori N, Oordt-Speets A, Rangaka MX, Reis A, Rotz L, Sandgren A, Sañé Schepisi M, Schünemann HJ, Sharma SK, Sotgiu G, Stagg HR, Sterling TR, Tayeb T, Uplekar M, van der Werf MJ, Vandevelde W, van Kessel F, van't Hoog A, Varma JK, Vezhnina N, Voniatis C, Vonk Noordegraaf-Schouten M, Weil D, Weyer K, Wilkinson RJ, Yoshiyama T, Zellweger JP, Raviglione M.

Eur Respir J. 2015 Dec;46(6):1563-76. doi: 10.1183/13993003.01245-2015. Epub 2015 Sep 24. Review.

25.

A sensitive urinary lipoarabinomannan test for tuberculosis.

Hamasur B, Bruchfeld J, van Helden P, Källenius G, Svenson S.

PLoS One. 2015 Apr 23;10(4):e0123457. doi: 10.1371/journal.pone.0123457. eCollection 2015.

26.

Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

Davies Forsman L, Giske CG, Bruchfeld J, Schön T, Juréen P, Ängeby K.

Antimicrob Agents Chemother. 2015;59(6):3630-2. doi: 10.1128/AAC.00171-15. Epub 2015 Mar 30.

27.

Towards tuberculosis elimination: an action framework for low-incidence countries.

Lönnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, Goletti D, González Ochoa ER, LoBue P, Matteelli A, Njoo H, Solovic I, Story A, Tayeb T, van der Werf MJ, Weil D, Zellweger JP, Abdel Aziz M, Al Lawati MR, Aliberti S, Arrazola de Oñate W, Barreira D, Bhatia V, Blasi F, Bloom A, Bruchfeld J, Castelli F, Centis R, Chemtob D, Cirillo DM, Colorado A, Dadu A, Dahle UR, De Paoli L, Dias HM, Duarte R, Fattorini L, Gaga M, Getahun H, Glaziou P, Goguadze L, Del Granado M, Haas W, Järvinen A, Kwon GY, Mosca D, Nahid P, Nishikiori N, Noguer I, O'Donnell J, Pace-Asciak A, Pompa MG, Popescu GG, Robalo Cordeiro C, Rønning K, Ruhwald M, Sculier JP, Simunović A, Smith-Palmer A, Sotgiu G, Sulis G, Torres-Duque CA, Umeki K, Uplekar M, van Weezenbeek C, Vasankari T, Vitillo RJ, Voniatis C, Wanlin M, Raviglione MC.

Eur Respir J. 2015 Apr;45(4):928-52. doi: 10.1183/09031936.00214014. Review.

28.

Tuberculosis and HIV Coinfection.

Bruchfeld J, Correia-Neves M, Källenius G.

Cold Spring Harb Perspect Med. 2015 Feb 26;5(7):a017871. doi: 10.1101/cshperspect.a017871. Review.

29.

Risk assessment of tuberculosis in immunocompromised patients. A TBNET study.

Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG, Domínguez J, Duarte R, Ernst M, Eyuboglu FO, Gerogianni I, Girardi E, Goletti D, Janssens JP, Julander I, Lange B, Latorre I, Losi M, Markova R, Matteelli A, Milburn H, Ravn P, Scholman T, Soccal PM, Straub M, Wagner D, Wolf T, Yalcin A, Lange C; TBNET.

Am J Respir Crit Care Med. 2014 Nov 15;190(10):1168-76. doi: 10.1164/rccm.201405-0967OC.

PMID:
25303140
30.

Intra- and extracellular activities of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosis.

Davies Forsman L, Schön T, Simonsson US, Bruchfeld J, Larsson M, Juréen P, Sturegård E, Giske CG, Ängeby K.

Antimicrob Agents Chemother. 2014 Dec;58(12):7557-9. doi: 10.1128/AAC.02995-14. Epub 2014 Sep 22.

31.

Comparison between RFLP and MIRU-VNTR genotyping of Mycobacterium tuberculosis strains isolated in Stockholm 2009 to 2011.

Jonsson J, Hoffner S, Berggren I, Bruchfeld J, Ghebremichael S, Pennhag A, Groenheit R.

PLoS One. 2014 Apr 14;9(4):e95159. doi: 10.1371/journal.pone.0095159. eCollection 2014.

32.

Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?

Arkema EV, Jonsson J, Baecklund E, Bruchfeld J, Feltelius N, Askling J; ARTIS Study Group.

Ann Rheum Dis. 2015 Jun;74(6):1212-7. doi: 10.1136/annrheumdis-2013-204960. Epub 2014 Mar 7.

PMID:
24608401
33.

Completing treatment for latent tuberculosis: patient background matters.

Kan B, Kalin M, Bruchfeld J.

Int J Tuberc Lung Dis. 2013 May;17(5):597-602. doi: 10.5588/ijtld.12.0692.

PMID:
23575323
34.

Extensive nosocomial transmission of tuberculosis in a low-incidence country.

Jonsson J, Kan B, Berggren I, Bruchfeld J.

J Hosp Infect. 2013 Apr;83(4):321-6. doi: 10.1016/j.jhin.2012.11.028. Epub 2013 Feb 21.

PMID:
23433580
35.

Immune responses to ESAT-6 and CFP-10 by FASCIA and multiplex technology for diagnosis of M. tuberculosis infection; IP-10 is a promising marker.

Borgström E, Andersen P, Atterfelt F, Julander I, Källenius G, Maeurer M, Rosenkrands I, Widfeldt M, Bruchfeld J, Gaines H.

PLoS One. 2012;7(11):e43438. doi: 10.1371/journal.pone.0043438. Epub 2012 Nov 8.

36.

Detection of proliferative responses to ESAT-6 and CFP-10 by FASCIA assay for diagnosis of Mycobacterium tuberculosis infection.

Borgström E, Andersen P, Andersson L, Julander I, Källenius G, Maeurer M, Norrby M, Rosenkrands I, Tecleab T, Bruchfeld J, Gaines H.

J Immunol Methods. 2011 Jul 29;370(1-2):55-64. doi: 10.1016/j.jim.2011.05.008. Epub 2011 May 30.

PMID:
21641911
37.

A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis.

Ruhwald M, Dominguez J, Latorre I, Losi M, Richeldi L, Pasticci MB, Mazzolla R, Goletti D, Butera O, Bruchfeld J, Gaines H, Gerogianni I, Tuuminen T, Ferrara G, Eugen-Olsen J, Ravn P; TBNET.

Tuberculosis (Edinb). 2011 May;91(3):260-7. doi: 10.1016/j.tube.2011.01.001. Epub 2011 Apr 2.

PMID:
21459676
38.

Genomic stability over 9 years of an isoniazid resistant Mycobacterium tuberculosis outbreak strain in Sweden.

Sandegren L, Groenheit R, Koivula T, Ghebremichael S, Advani A, Castro E, Pennhag A, Hoffner S, Mazurek J, Pawlowski A, Kan B, Bruchfeld J, Melefors Ö, Källenius G.

PLoS One. 2011 Jan 31;6(1):e16647. doi: 10.1371/journal.pone.0016647.

39.

Human immunodeficiency virus associated tuberculosis more often due to recent infection than reactivation of latent infection.

Houben RM, Crampin AC, Ndhlovu R, Sonnenberg P, Godfrey-Faussett P, Haas WH, Engelmann G, Lombard CJ, Wilkinson D, Bruchfeld J, Lockman S, Tappero J, Glynn JR.

Int J Tuberc Lung Dis. 2011 Jan;15(1):24-31. Review.

PMID:
21276292
40.

African 2, a clonal complex of Mycobacterium bovis epidemiologically important in East Africa.

Berg S, Garcia-Pelayo MC, Müller B, Hailu E, Asiimwe B, Kremer K, Dale J, Boniotti MB, Rodriguez S, Hilty M, Rigouts L, Firdessa R, Machado A, Mucavele C, Ngandolo BN, Bruchfeld J, Boschiroli L, Müller A, Sahraoui N, Pacciarini M, Cadmus S, Joloba M, van Soolingen D, Michel AL, Djønne B, Aranaz A, Zinsstag J, van Helden P, Portaels F, Kazwala R, Källenius G, Hewinson RG, Aseffa A, Gordon SV, Smith NH.

J Bacteriol. 2011 Feb;193(3):670-8. doi: 10.1128/JB.00750-10. Epub 2010 Nov 19. Erratum in: J Bacteriol. 2012 Mar;194(6):1641.

41.

Drug resistant Mycobacterium tuberculosis of the Beijing genotype does not spread in Sweden.

Ghebremichael S, Groenheit R, Pennhag A, Koivula T, Andersson E, Bruchfeld J, Hoffner S, Romanus V, Källenius G.

PLoS One. 2010 May 28;5(5):e10893. doi: 10.1371/journal.pone.0010893.

42.

Extensive transmission of an isoniazid-resistant strain of Mycobacterium tuberculosis in Sweden.

Kan B, Berggren I, Ghebremichael S, Bennet R, Bruchfeld J, Chryssanthou E, Källenius G, Petersson R, Petrini B, Romanus V, Sylvan S, Kalin M.

Int J Tuberc Lung Dis. 2008 Feb;12(2):199-204.

PMID:
18230254
43.

Pneumocystis jiroveci pneumonia and other pulmonary infections in TB smear-negative HIV-positive patients with atypical chest X-ray in Ethiopia.

Aderaye G, Bruchfeld J, Aseffa G, Nigussie Y, Melaku K, Woldeamanuel Y, Asrat D, Worku A, Gaegziabher H, Lebaad M, Lindquist L.

Scand J Infect Dis. 2007;39(11-12):1045-53. Epub 2007 Jul 2.

PMID:
17852928
44.
45.
46.

Occurrence of Pneumocystis carinii in HIV-positive patients with suspected pulmonary tuberculosis in Ethiopia.

Aderaye G, Bruchfeld J, Olsson M, Lindquist L.

AIDS. 2003 Feb 14;17(3):435-40.

PMID:
12556698
47.
48.

Evaluation of outpatients with suspected pulmonary tuberculosis in a high HIV prevalence setting in Ethiopia: clinical, diagnostic and epidemiological characteristics.

Bruchfeld J, Aderaye G, Palme IB, Bjorvatn B, Britton S, Feleke Y, Källenius G, Lindquist L.

Scand J Infect Dis. 2002;34(5):331-7.

PMID:
12069014
49.
50.

A controlled estimate of the risk of HIV infection in Ethiopian children with tuberculosis.

Berggren Palme I, Gudetta B, Degefu H, Muhe L, Bruchfeld J, Giesecke J.

Epidemiol Infect. 2001 Dec;127(3):517-25.

Supplemental Content

Loading ...
Support Center